KemPharm announces FDA approval of Apadaz™ (benzhydrocodone and acetaminophen)
KemPharm announced the FDA approved its NDA for Apadaz™ for short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Apadaz is an immediate release combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen. February 23, 2018